Le Lézard
Classified in: Health, Business
Subjects: FNC, VEN

OrbiMed Raises $4.3 Billion Across Private Investment Funds


NEW YORK, Oct. 24, 2023 /PRNewswire/ -- OrbiMed, a global healthcare investment firm, is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV. 

OrbiMed

Consistent with their predecessors, these new funds enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities. OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services. 

OrbiMed is led by its 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance. The firm's professionals are based in a dozen global locations across key healthcare markets in North America, Europe and Asia.

Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. 

"OrbiMed is deeply appreciative of the continued support we've received from many long-standing partners who've invested in these funds," said Carter Neild, a Managing Partner of OrbiMed. "We will endeavor to meet our partners' high expectations in the coming years."

About OrbiMed
OrbiMed is a leading healthcare investment firm with more than $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed's team of more than 130 professionals is based in New York City; London; San Francisco; Shanghai; Hong Kong; Mumbai, India; Herzliya, Israel; and other key global markets. For more information, please visit www.orbimed.com. Follow us on X (formerly Twitter) @OrbiMed.

Media Contact:
Carter Neild, CFA 
Phone: (212) 739.6400 
Email: [email protected]

Erin Bocherer 
Phone: (678) 294-2258
Cogenta Communications for OrbiMed
Email: [email protected]

Logo - https://mma.prnewswire.com/media/2251647/OrbiMed_Logo.jpg 


These press releases may also interest you

at 12:00
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...

at 12:00
SightMD Pennsylvania, a leading multi-specialty ophthalmology platform, is pleased to announce the acquisition of James Lewis, MD. Through this strategic partnership, Dr. Lewis's practice at 8380 Old York Rd Ste 110, Elkins Park, PA 19027 will expand...

at 11:14
Today, the Minister of Labour, Seamus O'Regan Jr., issued the following statement marking the National Day of Mourning:  "Everyone has the right to a safe, healthy and respectful workplace. This is a widely shared belief in Canada, but it is not yet...

at 10:15
Pomerantz LLP announces that a class action lawsuit has been filed against Lincoln National Corporation ("Lincoln National" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or...

at 10:15
Pomerantz LLP is investigating claims on behalf of investors of Lamb Weston Holdings, Inc.  ("Lamb Weston" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  ...

at 10:15
Pomerantz LLP is investigating claims on behalf of investors of  Autodesk, Inc. ("Autodesk" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....



News published on and distributed by: